Lyso­gene rais­es $25M in Paris IPO; Chan Zucker­berg Bio­hub starts hand­ing out $50M

• The gene ther­a­py com­pa­ny Lyso­gene has raised $25 mil­lion from an IPO on Eu­ronext Paris de­signed to fund its R&D work. “This IPO will en­able us to pur­sue the de­vel­op­ment of two drugs to treat two polys­dis­abling, dev­as­tat­ing and dead­ly dis­eases of the cen­tral ner­vous sys­tem, which start in in­fan­cy and lead to the pa­tients pre­ma­ture death,” said CEO Karen Aiach. “By fo­cus­ing di­rect­ly on the cause, our treat­ments aim to cure these dis­eases the med­ical needs of which are large­ly un­sat­is­fied and cur­rent­ly un­cov­ered.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.